| Title |
Trastuzumab containing regimens for early breast cancer
|
|---|---|
| Published in |
Cochrane database of systematic reviews, April 2012
|
| DOI | 10.1002/14651858.cd006243.pub2 |
| Pubmed ID | |
| Authors |
Lorenzo Moja, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri, Roberto D'Amico |
| Abstract |
Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on efficacy seem to support its use, there are potential cardiac toxicities which need to be considered, especially for women at lower risk of recurrence, or those at increased cardiovascular risk. |
X Demographics
The data shown below were collected from the profiles of 56 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 12 | 21% |
| United States | 4 | 7% |
| Belgium | 1 | 2% |
| Brazil | 1 | 2% |
| Nepal | 1 | 2% |
| Spain | 1 | 2% |
| Unknown | 36 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 51 | 91% |
| Practitioners (doctors, other healthcare professionals) | 5 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 524 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 3 | <1% |
| Canada | 3 | <1% |
| Korea, Republic of | 2 | <1% |
| United States | 2 | <1% |
| Chile | 1 | <1% |
| United Kingdom | 1 | <1% |
| Austria | 1 | <1% |
| Greece | 1 | <1% |
| Brazil | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 509 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 59 | 11% |
| Student > Master | 58 | 11% |
| Researcher | 57 | 11% |
| Student > Ph. D. Student | 48 | 9% |
| Student > Postgraduate | 46 | 9% |
| Other | 94 | 18% |
| Unknown | 162 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 210 | 40% |
| Biochemistry, Genetics and Molecular Biology | 26 | 5% |
| Agricultural and Biological Sciences | 26 | 5% |
| Nursing and Health Professions | 22 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 4% |
| Other | 44 | 8% |
| Unknown | 174 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 160. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2024.
All research outputs
#259,015
of 25,837,817 outputs
Outputs from Cochrane database of systematic reviews
#427
of 13,149 outputs
Outputs of similar age
#1,073
of 176,588 outputs
Outputs of similar age from Cochrane database of systematic reviews
#4
of 185 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,149 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,588 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 185 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.